Phase 3
๐ Investigational Drug / Biologic
NCT06170788
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) โฅ 50% (MK-2870-007)
๐ Mayo Clinic in Arizona - Phoenix ( Site 0147) โ Phoenix, Arizona
View Study & Screener โ